Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (519)	4/30/2001 5:20:43 PM
From: BulbaMan	Read Replies (2) \| Respond to of 1833

Arena just filed its 8k reporting its deal with Axiom. The 8K lists the shareholdings of Cadus (see below) and puts a $3.50 value on the Axiom preferred shares sold to Arena. From reading the 8K it seems the Axiom preferred shares owned by Cadus would be equivalent to those just bought by Arena. So, Cadus' 2.1 million shares of Axiom appear to be valued at about $7.35 million or roughly $.55 per Cadus share. All comments appreciated. Owned or Controlled By: Series B Series C Series D Series E Cadus 2,109,161 N/A N/A N/A Jafco N/A 1,373,295 N/A N/A Biacore N/A N/A 1,333,333 N/A Arena N/A N/A N/A 571,429